10-Q: Marpai Reports Q3 2026 Results Amidst Going Concern Doubts

Marpai, Inc. filed its Q3 2026 10-Q, revealing a net loss of $3.3 million for the quarter and highlighting substantial doubt about its ability to continue as a going concern.

Summary

• Marpai, Inc. reported its third-quarter and nine-month results for the period ending September 30, 2026.
• For the three months ended September 30, 2026, revenue increased by 9.6% to $4.4 million, driven by growth in ancillary services.
• However, the company incurred a net loss of $3.3 million for the quarter and $11.1 million for the nine months ended September 30, 2026.
• Operating cash flow was negative at $11.6 million for the nine-month period.
• The company has substantial doubt about its ability to continue as a going concern due to its liquidity position, accumulated deficit of $126.4 million, and negative working capital of $5.5 million.
• Marpai raised $12.1 million in gross proceeds from the sale of Series A Preferred Stock in July 2026.
• The company is actively seeking additional capital through equity or debt issuance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's continued net losses, significant cash burn, and substantial doubt about its ability to continue as a going concern, despite some revenue growth in the quarter.

Positives

• Revenue for the three months ended September 30, 2026, increased by 9.6% to $4.4 million, primarily due to growth in ancillary services.
• Information technology and sales and marketing expenses decreased by 9.3% and 49.5% respectively for the three-month period, indicating operational streamlining.
• The company successfully raised $12.1 million in gross proceeds from the issuance of Series A Preferred Stock in July 2026.
• The company repaid $2.45 million to AXA in September 2026 as per the AXA Amendment terms.
• The company repaid $1.0 million related party advance and $660 thousand of related party loans during the nine months ended September 30, 2026.

Negatives

• The company reported a net loss of $3.3 million for the three months ended September 30, 2026, and $11.1 million for the nine months ended September 30, 2026.
• Net revenue for the nine months ended September 30, 2026, decreased by 7.6% to $13.0 million, attributed to customer turnover.
• Operating cash flow was a negative $11.6 million for the nine months ended September 30, 2026.
• The company has an accumulated deficit of $126.4 million as of September 30, 2026.
• Negative working capital was approximately $5.5 million as of September 30, 2026.
• The company's liquidity condition raises substantial doubt about its ability to continue as a going concern.
• Interest expense increased by 7.5% to $857 thousand for the three months ended September 30, 2026, and by 17.7% to $2.9 million for the nine months ended September 30, 2026.

Risks

• The company's liquidity condition raises substantial doubt about its ability to continue as a going concern.
• The company depends on a few major customers for a significant portion of its revenue, and losing these customers could adversely affect its results.
• The review of strategic alternatives may be costly, time-consuming, and disruptive to business operations.
• There is no assurance that any strategic transaction will be successful or provide additional value to stockholders.
• The company may be unable to raise additional capital, which could materially impact its ability to operate and invest in its product portfolio.
• Any future debt or equity transactions may cause significant dilution to existing stockholders.
• The company's ability to attract and retain qualified personnel and key employees may be impacted by uncertainties related to its future.

Future Outlook

The company projects a continued need for additional capital to fund operations and investments until revenue levels permit cash self-sufficiency. Management anticipates raising this capital through equity and/or debt issuance, or potentially asset sales. Failure to secure additional capital could lead to scaled-back operations or asset divestitures.

Management Comments

• Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern through twelve months from the date these unaudited interim condensed consolidated financial statements are issued.
• Management continues to evaluate additional funding alternatives and is seeking to raise additional funds through the issuance of equity or debt securities.
• If we are unable to raise additional capital moving forward, our ability to operate in the normal course and continue to invest in our product portfolio may be materially and adversely impacted and we may be forced to scale back operations or divest some or all of our assets.

Industry Context

StockSavvy.ai notes that Marpai operates in the competitive healthcare administration and TPA market. The company's focus on a technology-driven approach to lower healthcare costs and improve outcomes is a strategic differentiator, but the current financial performance and going concern issues highlight the challenges in scaling such a business in the current economic climate.

Comparison to Industry Standards

• The company's net loss of $3.3 million for the quarter and $11.1 million for the nine months is a significant concern when compared to profitable TPA companies.
• The negative operating cash flow of $11.6 million for the nine months is a critical indicator of financial distress, contrasting with industry players that typically generate positive cash flow from operations.
• The substantial doubt about going concern is a severe red flag, rarely seen in established, stable companies within the healthcare services sector.
• While revenue growth in the quarter is positive, the overall revenue decline for the year-to-date period suggests challenges in customer retention or market penetration compared to industry growth rates.

Legal Proceedings

• The company settled a civil complaint by Messer Financial Group Inc. for breach of contract, involving a cash payment, issuance of restricted shares for attorneys' fees, and installment payments of RSUs over time, with a potential additional cash payment or stock issuance in January 2028 if the stock consideration's total value is less than $1.0 million.

Related Party Transactions

• Promissory notes totaling $660 thousand were issued to the CEO and subsequently repaid.
• Interest expense of $26 thousand was recorded related to these notes.
• The company received a $500 thousand advance payment from a related party for future TPA services, which was fully recognized.
• A $1.0 million refundable cash advance was received from a related party and subsequently repaid.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and uncertainty regarding the company's going concern status.
• Creditors and debenture holders face increased risk due to the company's liquidity challenges and going concern doubts.
• Employees may face uncertainty regarding job security if operations are scaled back or assets are divested.
• Customers may experience service disruptions if the company is unable to secure necessary funding.

Next Steps

• Continue to seek additional capital through equity or debt issuance.
• Manage operations and capital investment requirements until revenue levels permit cash self-sufficiency.
• Potentially scale back operations or divest assets if additional capital cannot be secured.
• Continue to evaluate strategic alternatives.

Key Dates

Recommendation

The company's persistent net losses, negative operating cash flow, and explicit statement of substantial doubt about its ability to continue as a going concern present significant financial distress. While there was some revenue growth in the quarter, it does not offset the fundamental financial instability. The need for continuous capital raises and the potential for significant dilution make this a high-risk investment.

Keywords

Third Party Administrator, Healthcare Administration, TPA Services, Self-Insured Employers, Healthcare Technology, Value-Based Healthcare, Ancillary Services, PBM